The Maharashtra Food and Drug Administration’s latest enforcement figures point to a regulatory system trying to do more than conduct periodic raids. Between June 1 and August 31, 2026, the department conducted 12,083 food inspections, collected 37,604 food and drug samples, issued 5,269 improvement notices and suspended 603 food licences. It also seized food stock worth Rs 67.2 crore and reported 875 arrests in food cases.
The numbers, cited by FDA Commissioner Tukaram Mundhe, are significant not only because of their scale but because of the model the department says it is attempting to build around them. The FDA is seeking to move food and drug regulation from a seasonal enforcement exercise to a continuing public-health mission based on three principles: empowering citizens, enabling compliant businesses and enforcing the law against those that ignore safety requirements.
That approach places the regulator inside an urban system that extends well beyond factories and shops. Food is prepared at weddings, community gatherings, school canteens, restaurants and delivery kitchens. Medicines move through hospitals, pharmacies and informal purchasing networks. Complaints arise across a large and diverse state, while inspections, laboratory testing, licensing and enforcement must be connected quickly enough to protect consumers.
The central administrative problem is capacity. The FDA’s sanctioned strength is 1,271 staff, while a roadmap submitted by Mundhe to the government estimates that nearly three times that number would be required to meet expected regulatory norms for Maharashtra’s size and complexity. The department says its recent increase in activity was achieved without a rise in sanctioned manpower, through tighter processes and digital systems.
This is where the administration’s technology strategy becomes important. The FDA’s online system can record the location and details of complaints, assign them to an appropriate officer and set a deadline for response. If action is not taken within the stipulated period, higher authorities can be alerted automatically. The system also creates an audit trail, allowing senior officials to monitor how a complaint was handled and reducing dependence on individual discretion.
The proposed use of artificial intelligence is similarly framed as an administrative tool rather than a replacement for regulatory staff. According to Mundhe, the objective is to allow existing personnel to handle a larger workload and focus human attention where it is most needed. The department is examining how inspection records, laboratory results, complaints, licensing information and previous violations can be combined to identify patterns and flag establishments or products requiring closer scrutiny.
That design could change the logic of inspection. A conventional enforcement system often reacts to complaints, visible violations or festival-related demand. A connected system can potentially use earlier violations, test results and complaint patterns to determine where scarce inspection capacity should be directed. The supplied material does not establish the system’s outcomes or accuracy, but it does show an attempt to create a more traceable process in which regulatory decisions can be monitored after they are made.
The enforcement figures show the breadth of the workload. On the drug side, the FDA conducted 2,902 inspections and seized illegal medicines and cosmetics worth Rs 11.41 crore. The department also registered 644 FIRs related to gutkha, reported 867 arrests in its three-month crackdown and seized banned gutkha and pan masala stocks worth Rs 19.62 crore.
The article also cites another set of departmental figures for the same broad period. These include inspections of 607 drug manufacturing establishments and nearly 2,300 pharmacies, with more than 32,000 of over 37,000 collected samples tested. The variation between the figures reported for different activities underlines the scale and complexity of the FDA’s work, but the department’s stated direction is clear: enforcement is being combined with laboratory testing, licensing action and data management rather than treated as a single raid-based activity.
Antibiotic misuse illustrates why regulation cannot stop at seizure statistics. Mundhe has raised concerns about the purchase of Schedule H medicines without prescriptions and about patients failing to complete prescribed courses. The FDA has tightened action against pharmacies over what it describes as unscientific and unprescribed antibiotic use, cancelling and suspending pharmacy licences as part of its enforcement efforts.
This issue connects everyday consumer behaviour to a wider public-health concern. The department’s intervention is not limited to whether a pharmacy holds a valid licence. It also concerns how medicines are sold, how consumers access them and whether established safeguards are being followed. The supplied material does not provide a quantified assessment of antimicrobial resistance in Maharashtra, but it identifies antibiotic misuse as one of the areas receiving greater regulatory attention.
The FDA has also entered a difficult area where consumer protection, hospital administration and pricing intersect. Mundhe said patients should not be forced to purchase medicines exclusively from a hospital’s in-house pharmacy and should be free to buy them elsewhere. He also flagged margins on hospital consumables such as syringes, saline and basic disposables, saying they can reach as high as 2,000%.
The Maharashtra FDA does not have direct authority to cap such prices, according to the report. Mundhe has instead recommended that the National Pharmaceutical Pricing Authority bring hospital consumables under regulated pricing. The distinction matters because it shows the limits of a state regulator’s mandate. A department may identify a problem affecting patients but still require another authority to change the pricing framework.
The same question arises in the department’s examination of generic medicines. Early findings cited in the material suggest that discounts in some cases are only 10% to 20% off branded rates. The evidence supplied does not establish how widespread that pattern is or how prices compare across all pharmacies, but it raises a basic test for affordability policy: whether the formal availability of generic medicines translates into meaningful savings for patients.
On the food side, the FDA has intensified action against adulterated or non-compliant products. It imposed a one-year ban on the manufacture, storage, distribution and transportation of analogue paneer, saying testing and reporting had helped restrict the product. The department is also working on environmental and safety measures related to food packaging, including a proposal to mandate food-grade, non-toxic ink for newsprint commonly used to wrap street food and an effort to reduce plastic in food packaging and delivery.
These measures expand the meaning of food regulation. Safety is not limited to the ingredients in a product. It also includes how food is stored, transported, packaged and served. However, the supplied material describes the packaging ink requirement as a proposal, not an implemented rule. That distinction is important in assessing what has changed and what remains under consideration.
The department’s treatment of weddings, community gatherings and other large events makes the same regulatory point from another direction. Food prepared for such events can be produced in substantial quantities outside conventional commercial kitchens. The FDA has issued compliance guidelines for caterers and event licensees and requires registration for these operations rather than excluding them because the events are informal.
The regulatory challenge is therefore partly one of visibility. Businesses with fixed premises may be easier to identify, licence and inspect. Temporary kitchens, caterers and event-based food operations require a system that can bring them into the formal compliance framework without assuming that informality eliminates public-health risk. The FDA’s stated approach is to combine enforcement with registration and guidance.
The department is also placing greater emphasis on prevention and public awareness. Under its “Safe Food for Every School Child” initiative, it conducted 270 workshops involving 60,990 schools across Maharashtra between April 1 and September 11, 2026. The programme focused on nutrition, clean diets and food-safety standards. The FDA said it had also ensured a “No High Fat, Sugar & Salt” requirement within 50 metres of school premises and promoted healthier alternatives to fried snacks and junk food in school canteens.
The school programme shows how the regulator is trying to act before a violation reaches an inspection file. It also reflects the department’s broader argument that food safety cannot be secured through enforcement alone. Citizens, licensees and the regulator are being treated as three connected stakeholders: the regulator must implement the law, businesses must comply and consumers must become more discerning.
Mundhe has linked this approach to changes in India’s disease burden, arguing that communicable diseases accounted for roughly 65% to 70% of the burden at Independence, while non-communicable diseases such as cancer, cardiac conditions and diabetes are dominant today. He has identified regular consumption of food high in fat, sugar and salt as a public-health concern rather than treating such consumption as an occasional festival-related issue. The supplied material presents this as the commissioner’s framing, not as a new department-wide statistical study.
The broader institutional question is whether a regulator can become more effective without first receiving the staffing levels it says are necessary. Digital complaint tracking, automated alerts, integrated records and AI-assisted prioritisation may improve the use of existing capacity. They cannot, on the evidence supplied, be treated as a substitute for laboratories, inspectors or enforcement officers. Nor can technology alone resolve gaps in authority, such as the FDA’s limited role in hospital-consumable pricing.
What the three-month figures establish is an administration attempting to widen the regulatory net while making its processes more visible and measurable. What they do not establish is the long-term effect of the crackdown on food safety, medicine affordability, antibiotic misuse or compliance rates. Those outcomes will depend on whether inspections lead to sustained correction, whether suspended licences remain compliant before restoration and whether citizens can see faster, more consistent responses to complaints.
The Maharashtra FDA’s stated mission is “Safe Food, Safe Drug, Safe Maharashtra”. Its emerging model combines enforcement, licensing, laboratory testing, digital monitoring and public education. The next measure of its success will not be the size of a single seizure or the number of arrests, but whether the system can turn intensive activity into durable compliance across the everyday spaces where people eat, buy medicines and receive care.
